AI Article Synopsis
- The study evaluates the effectiveness of low-dose leucovorin plus 5-fluorouracil (LV/5-FU) in elderly patients with advanced colorectal cancer.
- A review of 20 patients' records showed a low response rate of 15%, with most experiencing progressive disease, but a moderate disease control rate of 35%.
- Overall, patients had a median survival time of 18.4 months, indicating that low-dose LV/5-FU may be a viable option for managing treatment with fewer severe side effects.
Article Abstract
Aim: To assess the practical efficacy of low-dose leucovorin plus 5-fluorouracil (LV/5-FU) in elderly patients with metastatic colorectal cancer.
Patients And Methods: The records of 20 patients treated with LV/5-FU for unresectable metastatic disease from colorectal cancer from 1999 to 2004 were retrospectively reviewed. The patients received LV/5-FU as first-line, and low-dose CPT-11 and CDDP regimen (CPT-11/CDDP) as second-line therapy.
Results: In the treatment of LV/5-FU, no patients had CR, 3 patients had PR, 4 patients had SD and 13 patients had PD, which results in a response rate (RR) of 15% and in a disease control rate (DCR) of 35%. MST of all patients was 18.4 months. There was one patient who experienced grade 3 or 4 adverse reactions during the course of these regimens.
Conclusion: Low-dose LV/5-FU chemotherapy in elderly patients with metastatic colorectal cancer could be acceptable in order to avoid adverse effects and to obtain quite a favorable survival time.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!